Rigel Pharmaceuticals Inc (NAS:RIGL)
$ 16.5 -0.76 (-4.4%) Market Cap: 304.04 Mil Enterprise Value: 303.15 Mil PE Ratio: 75.04 PB Ratio: 0 GF Score: 77/100

Rigel Pharmaceuticals Inc at Citi BioPharma Conference (Virtual) Transcript

Sep 10, 2021 / 04:30PM GMT
Release Date Price: $38.7 (-3.25%)
Yigal Dov Nochomovitz
Citigroup Inc., Research Division - Director

Okay, great. Welcome, everyone. This is a multi-company panel entitled Sickle Cell, Beta-Thal, ITP & PKD - Measuring Industry Progress in Benign Hematology. It's my pleasure to introduce the guests on the panel.

From Agios Pharmaceuticals, Jackie Fouse, who is the CEO of the company. Hi, Jackie. From Rigel Pharmaceuticals, Raul Rodriguez, the President and CEO; and Jonathan Schwartz, who is the CMO at Rocket Pharmaceuticals. And we have a fourth participant and hopefully will show up soon, Rahul Ballal, the CEO of IMARA. So welcome all of you. Thank you very, very much for your participation.

Questions & Answers

Yigal Dov Nochomovitz;Jacqualyn A.
Citigroup Inc., Research Division - Director

Maybe to get things started, for those less familiar with your companies and your pipelines, if each of you could spend 2 or 3 minutes just doing a high level, a summary of what you're focused on and what your pipeline looks like. Jackie, you want to kick it off?

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot